Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2435-2442

  Arendrup, Maiken Cavling ^a   Perlin, David S ^b   Jensen, Rasmus Hare ^a   Howard, Susan Julie ^c   Goodwin, Joanne ^c   Hope, William ^c  

^a STATENS SERUM INSTITUT   (Denmark)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; MICAFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CANDIDA GLABRATA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FKS GENE; FUNGAL VIRULENCE; FUNGUS ISOLATION; GENE; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOCOMPETENCE; IN VIVO STUDY; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CANDIDA GLABRATA; CANDIDIASIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; GENES, FUNGAL; GLUCOSYLTRANSFERASES; HUMANS; KIDNEY; LIPOPEPTIDES; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 84860187010     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06369-11     Document Type: Article

References (44)

1. Andes D, et al. 2010. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob. Agents Chemother. 54:2497-2506.
2. Arendrup MC. 2010. Epidemiology of invasive candidiasis. Curr. Opin. Crit. Care 16:445- 452.
3. Arendrup MC, et al. 2009. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob. Agents Chemother. 53:1185-1193.
4. Arendrup MC, et al. 2010. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and Isosensitest media. Antimicrob. Agents Chemother. 54:426-439.
5. Arendrup MC, Park S, Brown S, Pfaller M, Perlin DS. 2011. Evaluation of caspofungin and micafungin CLSI M44-A2 disk diffusion and associated breakpoints testing using a well characterized panel of wild type and fks hot spot mutant Candida isolates. Antimicrob. Agents Chemother. 55:1891-1895.
6. Arendrup MC, et al. 2011. Echinocandin susceptibility testing of Candida spp. using the EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time and drug lots. Antimicrob. Agents Chemother. 55:1580 -1587.
7. Arendrup MC, et al. 2011. Diagnostic issues, clinical characteristics, and outcome for patients with fungemia. J. Clin. Microbiol. 49:3300 -3308.
8. Baixench MT, et al. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59:1076-1083.
9. Ben-Ami R, et al. 2011. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J. Infect. Dis. 204:626-635.
10. Brillowska-Dabrowska A, Saunte DM, Arendrup MC. 2007. Five-hour diagnosis of dermatophyte nail infections with specific detection of Trichophyton rubrum. J. Clin. Microbiol. 45:1200 -1204.
11. Castanheira M, et al. 2010. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob. Agents Chemother. 54:2655-2659.
12. Cleary JD, Garcia-Effron G, Chapman SW, Perlin DS. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265. (Pubitemid 351758575)
13. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - third edition. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Clinical and Laboratory Standards Institute. 2009. Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition. CLSI document M44-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Dannaoui E, et al. 2010. Infections due to Candida spp. with reduced susceptibility to caspofungin in France, abstr. O346. Abstr. 20th Eur. Congr. Clin. Microbiol. Infect. Dis.
16. Desnos-Ollivier M, et al. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the EUCAST method. Antimicrob. Agents Chemother. 52:3092-3098.
17. Diack SL. 1930. The determination of the surface area of the white rat. J. Nutr. 3:289-296.
18. Ecalta. 2011. Ecalta: EPAR product information. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document -library/EPAR---Product-Information/human/000788/WC500020673.pdf.
19. Frimodt-Moller N, Sebbesen O, Frolund TV. 1983. The pneumococcus and the mouse protection test: importance of the lag phase in vivo. Chemotherapy 29:128 -134.
20. Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. 2008. Caspofungin- resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob. Agents Chemother. 52:4181- 4183.
21. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690 -3699.
22. Garcia-Effron G, Park S, Perlin DS. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
23. Garcia-Effron G, Park S, Perlin DS. 2009. Improved Candida spp. echinocandin susceptibility determination by the addition of bovine serum albumin (BSA). Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-352.
24. Hiemenz J, et al. 2005. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob. Agents Chemother. 49:1331-1336. (Pubitemid 40463357)
25. Howard SJ, et al. 2011. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob. Agents Chemother. 55:4880-4887.
26. Katiyar S, Pfaller M, Edlind T. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894. (Pubitemid 44198725)
27. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938 -944.
28. Kuse ER, et al. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised doubleblind trial. Lancet 369:1519 -1527.
29. Laverdiere M, et al. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.
30. Miller CD, Lomaestro BW, Park S, Perlin DS. 2006. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26:877- 880.
31. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
32. Pappas PG, et al. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45: 883-893. (Pubitemid 47580382)
33. Park S, et al. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264 -3273.
34. Pasquale T, Tomada JR, Ghannoun M, Dipersio J, Bonilla H. 2008. Emergence of Candida tropicalis resistant to caspofungin. J. Antimicrob. Chemother. 61:219.
35. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130. (Pubitemid 47031054)
36. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180 -195.
37. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163. (Pubitemid 46167771)
38. Pfeiffer CD, et al. 2010. Breakthrough invasive candidiasis in patients on micafungin. J. Clin. Microbiol. 48:2373-2380.
39. Reboli AC, et al. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482. (Pubitemid 46919773)
40. Rodriguez-Tudela JL, et al. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405. (Pubitemid 351356536)
41. Slater JL, et al. 2011. Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob. Agents Chemother. 55: 3075-3083.
42. Stone JA, et al. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745. (Pubitemid 34157659)
43. Wiederhold NP, Lewis JS. 2007. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin. Pharmacother. 8:1155-1166. (Pubitemid 46929308)
44. Wiederhold NP, Najvar LK, Bocanegra RA, Kirkpatrick WR, Patterson TF. 2011. Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob. Agents Chemother. 55:3254-3260.